[1] Reef SE, Plotkin SA. Rubella vaccines. In Plotkin SA, Orenstein WA, Offit PA, Edwards KM, editors. Plotkin’s Vaccines. Amsterdam: Elsevier. 2018; p. 970-1000.e18. http://dx.doi.org/10.1016/B978-0-323-35761-6.00052-3.
[2] Winter AK, Moss WJ. Rubella. Lancet 2022;399(10332):1336 − 46. https://doi.org/10.1016/S0140-6736(21)02691-XCrossRef
[3] Centers for Disease Control and Prevention. 5.1 Congenital Rubella Syndrome (CRS). 2020. https://www.cdc.gov/ncbddd/birthdefects/surveillancemanual/chapters/chapter-5/chapter5-1.html. [2023-12-27].
[4] Lambert N, Strebel P, Orenstein W, Icenogle J, Poland GA. Rubella. Lancet 2015;385(9984):2297 − 307. https://doi.org/10.1016/S0140-6736(14)60539-0CrossRef
[5] Su QR, Feng ZL, Hao LX, Ma C, Hagan JE, Grant GB, et al. Assessing the burden of congenital rubella syndrome in China and evaluating mitigation strategies: a metapopulation modelling study. Lancet Infect Dis 2021;21(7):1004 − 13. https://doi.org/10.1016/S1473-3099(20)30475-8CrossRef
[6] WHO Regional Office for the Western Pacific. Regional strategy and plan of action for measles and rubella elimination in the Western Pacific. https://www.who.int/publications/i/item/9789290618515. [2023-12-19].
[7] Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Statist Med 2000;19(3):335 − 51. https://doi.org/10.1002/(sici)1097-0258(20000215)19:3<335::aid-sim336>3.0.co;2-z.CrossRef
[8] Ma C, Su QR, Wen N, Fan CX, Yang H, Wang HQ, et al. Evaluation of the measles surveillance system performance in China, 2015-2016. Chin J Vaccines Immunization 2018;24(2):141 − 5. https://doi.org/10.19914/j.cjvi.2018.02.005CrossRef
[9] Su QR, Ma C, Wen N, Fan CX, Yang H, Wang HQ, et al. Epidemiological profile and progress toward rubella elimination in China. 10 years after nationwide introduction of rubella vaccine. Vaccine 2018;36(16):2079 − 85. https://doi.org/10.1016/j.vaccine.2018.03.013CrossRef
[10] Li YQ, Ma C, Hao LX, Wang FZ, Wen N, Yang H, et al. Epidemiology of rubella in China, 2018-2019. Chin J Vaccines Immunization 2021;27(1):62 − 6. https://doi.org/10.19914/j.cjvi.2021003CrossRef
[11] Zhu Z, Cui AL, Zhang Y, Mao NY, Liu Y, Liu L, et al. Transmission dynamics of the rubella virus circulating in China during 2010-2019: 2 lineage switches between genotypes 1E and 2B. Clin Infect Dis 2021;73(7):1157 − 64. https://doi.org/10.1093/cid/ciab339CrossRef
[12] Zhu Z, Abernathy E, Cui AL, Zhang Y, Zhou SJ, Zhang ZY, et al. Rubella virus genotypes in the People’s Republic of China between 1979 and 2007: a shift in endemic viruses during the 2001 Rubella Epidemic. J Clin Microbiol 2010;48(5):1775 − 81. https://doi.org/10.1128/JCM.02055-09CrossRef
[13] Liu Y, Cui AL, Guo JY, Deng LL, Fan LX, Wei H, et al. Epidemiology and genetic characteristics of rubella virus circulating in China in 2020. Chin J Virol 2021;37(3):638 − 47. https://doi.org/10.13242/j.cnki.bingduxuebao.003936CrossRef
[14] Zhang LL, Wang XY, Liu MJ, Feng GS, Zeng YP, Wang R, et al. The epidemiology and disease burden of congenital TORCH infections among hospitalized children in China: a national cross-sectional study. PLoS Negl Trop Dis 2022;16(10):e0010861. https://doi.org/10.1371/journal.pntd.0010861CrossRef
[15] Zhou QJ, Wang QM, Shen HP, Zhang YP, Zhang SK, Li XT, et al. Rubella virus immunization status in preconception period among Chinese women of reproductive age: a nation-wide, cross-sectional study. Vaccine 2017;35(23):3076 − 81. https://doi.org/10.1016/j.vaccine.2017.04.044CrossRef
[16] Durrheim DN, Xu AQ, Baker MG, Hsu LY, Takashima Y. China has the momentum to eliminate measles. Lancet Reg Health West Pac 2023;30:100669. https://doi.org/10.1016/j.lanwpc.2022.100669CrossRef
[17] World Health Organization. Rubella vaccines: WHO position paper. Wkly Epidemiol Rec 2011;86(29):301-16. https://pubmed.ncbi.nlm.nih.gov/21766537/.